Results 21 to 30 of about 187,044 (318)

Evaluation of dosing strategy for pembrolizumab for oncology indications

Journal for ImmunoTherapy of Cancer, 2017
Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability.
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone   +6 more
doaj   +1 more source

Affective temperament polygenic risk scores predict depression: investigating the role of environmental factors

European Psychiatry, 2023
Introduction Depressive disorders are known heterogeneous both in their clinical manifestations and etiopathophysiology. Affective temperaments have a strong biological background and heritability, manifest at early age and remain stable throughout the ...
D. Győrik, D. Torok, B. Erdelyi-Hamza, Z. Gal, N. Eszlari, G. Bagdy, G. Juhasz, X. Gonda   +7 more
doaj   +1 more source

Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine During Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania. [PDF]

, 2010
The combination of artemether (ARM) and lumefantrine is currently the first-line treatment of uncomplicated falciparum malaria in mainland Tanzania. While the exposure to lumefantrine has been associated with the probability of adequate clinical and ...
Annerberg, Anna, Ashton, Michael, Björkman, Anders, Dahlström, Sabina, Färnert, Anna, Gil, Pedro, Hietala, Sofia Friberg, Lindegårdh, Niklas, Mårtensson, Andreas, Ngasala, Billy, Premji, Zul   +10 more
core   +4 more sources

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours [PDF]

, 2016
Purpose: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the ...
Allen, Rodger, Anthoney, Alan, Banerji, Udai, Bevan, Paul, Boddy, Alan V., Buerkle, Markus, Coyle, Vicky, Cresti, Nicola, Dean, Emma, Drew, Yvette, Evans, T.R. Jefferey, Greystoke, Alastair, Griffin, Melanie J., Jamieson, David, Mala, Carola, Merriman, Mark, Plummer, Ruth, Ranson, Malcolm, Rodgers, Lisa, Sludden, Julieann, Swales, Karen, Wilson, Richard H.   +21 more
core   +2 more sources

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Journal of Hematology & Oncology, 2020
Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins.
Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock, Daohong Zhou   +15 more
doaj   +1 more source

Evaluation of novel epibatidine analogs in the rat nicotine drug discrimination assay and in the rat chronic constriction injury neuropathic pain model

Advances in Drug and Alcohol Research, 2023
Nicotine is the primary psychoactive component responsible for maintaining tobacco dependence in humans. Chronic pain is often a consequence of tobacco-related pathologies, and the development of a dual therapeutic that could treat chronic pain and ...
Kevin Luque-Sanchez, Jasmine Felix, Joshua Bilbrey, Luis Restrepo, Morgan Reeves, Lance R. McMahon, Lance R. McMahon, Jenny L. Wilkerson, Jenny L. Wilkerson   +8 more
doaj   +1 more source

The G protein‐coupled receptor ligand apelin‐13 ameliorates skeletal muscle atrophy induced by chronic kidney disease

Journal of Cachexia, Sarcopenia and Muscle, 2023
Background Targeting of the apelin–apelin receptor (Apj) system may serve as a useful therapeutic intervention for the management of chronic kidney disease (CKD)‐induced skeletal muscle atrophy.
Yuki Enoki, Tomoya Nagai, Yuna Hamamura, Sumika Osa, Hideaki Nakamura, Kazuaki Taguchi, Hiroshi Watanabe, Toru Maruyama, Kazuaki Matsumoto   +8 more
doaj   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model

Clinical and Translational Science, 2020
In the development of new drugs, the prediction of metabolite‐to‐parent plasma exposure ratio in humans prior to administration in a clinical study has emerged as an important need.
Ernesto Callegari, Manthena V.S. Varma, R. Scott Obach   +2 more
doaj   +1 more source

Eletriptan in the management of acute migraine. An update on the evidence for efficacy, safety, and consistent response [PDF]

, 2016
Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks.
Capi, Matilde, Curto, Martina, De Andrés, Fernando, Gentile, Giovanna, Lionetto, Luana, Martelletti, Paolo, Negro, Andrea   +6 more
core   +1 more source